Medicare AdvantageCoverageLow impact
MA07.027h, Autonomic Nervous System Testing
Independence Blue Cross·Neurology, Endocrinology, Cardiology +4 more·Medical Policy
Effective date
Jun 16, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross reissued MA07.027h (Autonomic Nervous System Testing) on 03/04/2026 to reaffirm the Company's continuing position on ANS testing coverage. The primary change was removal of the BILLING REQUIREMENT header; coverage criteria remain unchanged, with testing covered only when meeting specific diagnostic or clinical decision-making indications, and explicitly not covered for screening purposes.
Action Required
By 06/16/2025: Billing team should verify that claims submission processes for CPT codes 95921, 95922, and 95923 continue to require medical necessity documentation supporting one of the covered indications (diagnostic evaluation of vasomotor instability symptoms, severity assessment of diagnosed neuropathy, syncope differentiation, etc.). Ensure that claims are rejected or denied if submitted for screening purposes (asymptomatic individuals, routine diabetes screening, etc.). No workflow changes are needed as coverage criteria remain substantively unchanged; this is a reissue confirming existing policy positions. Monitor for any system notifications from Independence Blue Cross regarding the removal of the BILLING REQUIREMENT header and ensure no billing workflows reference that removed section.